Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone

Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the ris...

Full description

Bibliographic Details
Main Authors: Onome T. Abiri, Wiltshire C. N. Johnson
Format: Article
Language:English
Published: Taylor & Francis Group 2019-12-01
Series:Journal of Pharmaceutical Policy and Practice
Subjects:
Online Access:http://dx.doi.org/10.1186/s40545-019-0173-2
_version_ 1797401293037240320
author Onome T. Abiri
Wiltshire C. N. Johnson
author_facet Onome T. Abiri
Wiltshire C. N. Johnson
author_sort Onome T. Abiri
collection DOAJ
description Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the risks by taking appropriate preventative actions to help inform therapeutic decisions, promote rational use of medicines, guide risk management and communications is gradually growing but yet to be fully optimized. This study sought to assess the current status of pharmacovigilance in Sierra Leone since it became the 87th member of the World Health Organisation International Drug Monitoring Programme. This study evaluated the pharmacovigilance system in Sierra Leone through a comprehensive and system-based approach that covered the national medicines regulatory authority, health facilities and public health programmes. A descriptive cross-sectional study design was employed. Using a convenience sampling method, 14 respondents from the national medicines regulatory authority, six health facilities and six public health programmes were interviewed. Data were collected using a validated metric instrument: Indicator-Based Pharmacovigilance Assessment Tool. A scoring system was used for the quantification of assessment results with a score greater than 60% indicating that an organization has structural and policy frameworks to collect and collate safety data in a national database and evaluate the risks and benefits by both active and passive approaches. The study findings showed that the national medicines regulatory authority scored 79% and thus met the standard requirements of pharmacovigilance. On the other hand, the health facilities and public health programmes scored less than 60% indicating the need to fully operationalise pharmacovigilance frameworks at these levels. The study further demonstrated that the national medicine regulatory authority which hosts the national pharmacovigilance centre had functional pharmacovigilance structures and processes with potential to providing leadership in the implementation of pharmacovigilance in Sierra Leone.
first_indexed 2024-03-09T02:07:49Z
format Article
id doaj.art-a59479f3beba4edb9476cbb1b8ded26e
institution Directory Open Access Journal
issn 2052-3211
language English
last_indexed 2024-03-09T02:07:49Z
publishDate 2019-12-01
publisher Taylor & Francis Group
record_format Article
series Journal of Pharmaceutical Policy and Practice
spelling doaj.art-a59479f3beba4edb9476cbb1b8ded26e2023-12-07T15:28:02ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112019-12-0112110.1186/s40545-019-0173-212315102Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra LeoneOnome T. Abiri0Wiltshire C. N. Johnson1Department of Pharmacology, Faculty of Basic Medical Sciences, College of Medicine and Allied Health Sciences,Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmaceutical Sciences, College of Medicine and Allied Health Sciences,Few low and middle-income countries (LMIC) have fully operational pharmacovigilance structures, systems and legal framework to collect and collate safety data and evaluate the risks and benefits by active and passive approaches. However, in a LMIC such as Sierra Leone, the capacity to manage the risks by taking appropriate preventative actions to help inform therapeutic decisions, promote rational use of medicines, guide risk management and communications is gradually growing but yet to be fully optimized. This study sought to assess the current status of pharmacovigilance in Sierra Leone since it became the 87th member of the World Health Organisation International Drug Monitoring Programme. This study evaluated the pharmacovigilance system in Sierra Leone through a comprehensive and system-based approach that covered the national medicines regulatory authority, health facilities and public health programmes. A descriptive cross-sectional study design was employed. Using a convenience sampling method, 14 respondents from the national medicines regulatory authority, six health facilities and six public health programmes were interviewed. Data were collected using a validated metric instrument: Indicator-Based Pharmacovigilance Assessment Tool. A scoring system was used for the quantification of assessment results with a score greater than 60% indicating that an organization has structural and policy frameworks to collect and collate safety data in a national database and evaluate the risks and benefits by both active and passive approaches. The study findings showed that the national medicines regulatory authority scored 79% and thus met the standard requirements of pharmacovigilance. On the other hand, the health facilities and public health programmes scored less than 60% indicating the need to fully operationalise pharmacovigilance frameworks at these levels. The study further demonstrated that the national medicine regulatory authority which hosts the national pharmacovigilance centre had functional pharmacovigilance structures and processes with potential to providing leadership in the implementation of pharmacovigilance in Sierra Leone.http://dx.doi.org/10.1186/s40545-019-0173-2pharmacovigilance systemsindicatorspublic health programmeshealth facilities
spellingShingle Onome T. Abiri
Wiltshire C. N. Johnson
Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
Journal of Pharmaceutical Policy and Practice
pharmacovigilance systems
indicators
public health programmes
health facilities
title Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_full Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_fullStr Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_full_unstemmed Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_short Pharmacovigilance systems in resource-limited settings: an evaluative case study of Sierra Leone
title_sort pharmacovigilance systems in resource limited settings an evaluative case study of sierra leone
topic pharmacovigilance systems
indicators
public health programmes
health facilities
url http://dx.doi.org/10.1186/s40545-019-0173-2
work_keys_str_mv AT onometabiri pharmacovigilancesystemsinresourcelimitedsettingsanevaluativecasestudyofsierraleone
AT wiltshirecnjohnson pharmacovigilancesystemsinresourcelimitedsettingsanevaluativecasestudyofsierraleone